Cargando…
On the Site and Mechanism of Action of β(3)-Adrenoceptor Agonists in the Bladder
The clinical success of mirabegron as the first β(3)-adrenoceptor (AR) agonist for treatment of the overactive bladder (OAB) syndrome, has resulted in substantial interest in its site and mechanism of action. Even if the adrenergic innervation of the bladder and urethra has been well studied, the lo...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Continence Society
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380826/ https://www.ncbi.nlm.nih.gov/pubmed/28361520 http://dx.doi.org/10.5213/inj.1734850.425 |